KDR and glioblastoma: PFS rates in phase II clinical studies in recurrent glioblastoma patients receiving axitinib are favourable compared with those of other multi-RTK inhibitors such as sunitinib and pazopanib, but are not superior to historical bevacizumab outcomes.231,232 Cedarinib is another pan-VEGFR inhibitor and is one of few small molecule inhibitors to make it to phase III clinical trial in glioblastoma.